Researh programme: IL18BP targeting therapeutics - Conformation-X Therapeutics
Latest Information Update: 19 Apr 2024
At a glance
- Originator Conformation-X Therapeutics
- Class Antineoplastics
- Mechanism of Action Interleukin-18-binding-protein-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer